Recent Finacing
Recent Raise
MYR GmbH develops Myrcludex B, a hepatitis B and D entry inhibitor targeting the hepatocyte HBV receptor to block infection and intrahepatic viral spread, advancing toward HDV clinical trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors